NASDAQ:JANX - Nasdaq - US47103J1051 - Common Stock - Currency: USD
We recently published a list of Unknown Billionaire Phill Gross’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other unknown billionaire Phill Gross’ stock picks with huge upside potential. Phillip “Phill” Gross is a seasoned investor and influential […]
Hospital capital equipment spending in China continues to be sluggish. An improvement in the trade conflict will create upside potential for GE HealthCare, and management believes China is a long-term growth opportunity.
- Investors added just $62 billion to ETFs in April, the lowest since 2024. - Risk-off sentiment drove a record $11 billion of outflows from sector ETFs. - Short-term government bond funds saw their second-highest inflows ever.
We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head […]
We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Vertical Aerospace Ltd. (NYSE:EVTL) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head […]
Publicly traded firms relentlessly buying bitcoin for their balance sheet could result in 'significant buy pressure.'
We recently published a list of the 12 Best Up and Coming Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Janux Therapeutics Inc. (NASDAQ:JANX) stands against other up and coming stocks to buy according to Wall Street Analysts. Tom Lee, Fundstrat managing partner, […]
Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks.
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels.
Mentions: VIR